Equities research analysts expect ABIOMED, Inc. (NASDAQ:ABMD) to report $147.65 million in sales for the current fiscal quarter, according to Zacks. Five analysts have made estimates for ABIOMED’s earnings, with the lowest sales estimate coming in at $145.70 million and the highest estimate coming in at $149.45 million. ABIOMED posted sales of $114.67 million during the same quarter last year, which suggests a positive year over year growth rate of 28.8%. The business is expected to report its next earnings report on Thursday, January 25th.

On average, analysts expect that ABIOMED will report full-year sales of $147.65 million for the current fiscal year, with estimates ranging from $571.70 million to $580.46 million. For the next year, analysts forecast that the firm will report sales of $733.05 million per share, with estimates ranging from $720.10 million to $749.30 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover ABIOMED.

ABIOMED (NASDAQ:ABMD) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.16. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The firm had revenue of $132.80 million for the quarter, compared to analysts’ expectations of $131.18 million. During the same quarter last year, the firm earned $0.20 EPS. The company’s quarterly revenue was up 28.9% compared to the same quarter last year.

Several equities analysts have commented on ABMD shares. BidaskClub raised shares of ABIOMED from a “hold” rating to a “buy” rating in a research report on Thursday, August 10th. SunTrust Banks, Inc. started coverage on shares of ABIOMED in a research report on Friday, September 29th. They set a “buy” rating and a $195.00 target price on the stock. Jefferies Group LLC lifted their target price on shares of ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a research report on Friday, September 29th. Piper Jaffray Companies reissued a “buy” rating and set a $160.00 target price on shares of ABIOMED in a research report on Tuesday, August 29th. Finally, Zacks Investment Research raised shares of ABIOMED from a “sell” rating to a “buy” rating and set a $203.00 price target on the stock in a report on Monday, October 30th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. ABIOMED currently has a consensus rating of “Buy” and a consensus price target of $185.38.

ABIOMED (NASDAQ ABMD) opened at $198.45 on Tuesday. ABIOMED has a 1 year low of $103.53 and a 1 year high of $200.28. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.20 and a current ratio of 5.84. The company has a market cap of $8,831.73, a P/E ratio of 128.04, a price-to-earnings-growth ratio of 2.66 and a beta of 0.23.

In other news, VP Andrew J. Greenfield sold 11,282 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $169.32, for a total transaction of $1,910,268.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the transaction, the vice president now owns 56,757 shares of the company’s stock, valued at $10,139,070.48. The disclosure for this sale can be found here. Insiders sold a total of 28,628 shares of company stock valued at $4,978,890 over the last quarter. 7.00% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the stock. Huntington National Bank purchased a new position in ABIOMED in the second quarter worth $100,000. Seven Eight Capital LP purchased a new position in ABIOMED in the second quarter worth $100,000. Rehmann Capital Advisory Group bought a new stake in ABIOMED in the third quarter worth $202,000. Sigma Planning Corp bought a new stake in ABIOMED in the third quarter worth $206,000. Finally, Dorsey & Whitney Trust CO LLC bought a new stake in ABIOMED in the third quarter worth $215,000. Institutional investors own 90.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Brokerages Expect ABIOMED, Inc. (ABMD) Will Post Quarterly Sales of $147.65 Million” was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/28/brokerages-expect-abiomed-inc-abmd-will-post-quarterly-sales-of-147-65-million.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Get a free copy of the Zacks research report on ABIOMED (ABMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.